Efficacy of abatacept for arthritis in patients with an overlap syndrome between rheumatoid arthritis and systemic lupus erythematosus

Clinical and Developmental Immunology

Volumn 2013, Issue , 2013, Pages

  Ikeda, Kei ^a   Sanayama, Yoshie ^a   Makita, Sohei ^a   Hosokawa, Junichi ^a   Yamagata, Mieko ^a   Nakagomi, Daiki ^a   Takabayashi, Katsuhiko ^a   Nakajima, Hiroshi ^a  

^a CHIBA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTICITRULLINATED PROTEIN ANTIBODY; C REACTIVE PROTEIN; CYCLOSPORIN A; DNA ANTIBODY; ETANERCEPT; IMMUNOGLOBULIN G; METHOTREXATE; PREDNISOLONE; PROTEIN ANTIBODY; RHEUMATOID FACTOR; TACROLIMUS; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; ANTIRHEUMATIC AGENT; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNE DISEASE; BONE RADIOGRAPHY; CLINICAL ARTICLE; CLINICAL DISEASE ACTIVITY INDEX; DISEASE DURATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELBOW BURSITIS; ELBOW DISEASE; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOGLOBULIN BLOOD LEVEL; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OVERLAP SYNDROME; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; ARTHRITIS; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84890073578     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2013/697525     Document Type: Article

References (25)

1. Panush R. S., Edwards L., Longley S., Webster E., 'Rhupus' syndrome. Archives of Internal Medicine 1988 148 7 1633 1636 2-s2.0-0023762899
2. van Vugt R. M., Derksen R. H., Kater L., Bijlsma J. W. J., Deforming arthropathy or lupus and rhupus hands in systemic lupus erythematosus. Annals of the Rheumatic Diseases 1998 57 9 540 544 2-s2.0-0031691764 (Pubitemid 28474061)
3. Chan M. T., Owen P., Dunphy J., Cox B., Carmichael C., Korendowych E., McHugh N. J., Associations of erosive arthritis with anti-cyclic citrullinated peptide antibodies and MHC class II alleles in systemic lupus erythematosus. Journal of Rheumatology 2008 35 1 77 83 2-s2.0-38149021391
4. Ball E. M., Bell A. L., Lupus arthritis-do we have a clinically useful classification? Rheumatology 2012 51 5 771 779 2-s2.0-84860261622 10.1093/rheumatology/ker381 ker381
5. Gabba A., Piga M., Vacca A., Joint and tendon involvement in systemic lupus erythematosus: an ultrasound study of hands and wrists in 108 patients. Rheumatology 2012 51 12 2278 2285 10.1093/rheumatology/kes226
6. Eriksson C., Engstrand S., Sundqvist K.-G., Rantapää-Dahlqvist S., Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF α Annals of the Rheumatic Diseases 2005 64 3 403 407 2-s2.0-14144256349 10.1136/ard.2004.024182 (Pubitemid 40283050)
7. Charles P. J., Smeenk R. J., De Jong J., Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis and Rheumatism 2000 43 11 2383 2390
8. Costa M. F., Said N. R., Zimmermann B., Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Seminars in Arthritis and Rheumatism 2008 37 6 381 387 2-s2.0-44349171691 10.1016/j.semarthrit.2007.08.003 (Pubitemid 351734520)
9. De Bandt M., Sibilia J., Le Loët X., Prouzeau S., Fautrel B., Marcelli C., Boucquillard E., Siame J. L., Mariette X., Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Research & Therapy 2005 7 3 R545 R551 2-s2.0-21744446004
10. Debandt M., Vittecoq O., Descamps V., Le Loët X., Meyer O., Anti-TNF- α -induced systemic lupus syndrome. Clinical Rheumatology 2003 22 1 56 61 2-s2.0-0038460243 10.1007/s10067-002-0654-5 (Pubitemid 41510416)
11. Chogle A. R., Shah C. V., Murthy A. K., Role of anti-tumor necrosis factor- α blockers in inducing lupus erythematosus tumidus in 'rhupus syndrome'. Journal of Rheumatology 2011 38 6 1218 1219 2-s2.0-79957849753 10.3899/jrheum.101020
12. Schiff M., Keiserman M., Codding C., Songcharoen S., Berman A., Nayiager S., Saldate C., Li T., Aranda R., Becker J.-C., Lin C., Cornet P. L. N., Dougados M., Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Annals of the Rheumatic Diseases 2008 67 8 1096 1103 2-s2.0-47949106400 10.1136/ard.2007.080002
13. Westhovens R., Robles M., Ximenes A. C., Nayiager S., Wollenhaupt J., Durez P., Gomez-Reino J., Grassi W., Haraoui B., Shergy W., Park S.-H., Genant H., Peterfy C., Becker J.-C., Covucci A., Helfrick R., Bathon J., Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Annals of the Rheumatic Diseases 2009 68 12 1870 1877 2-s2.0-65349176911 10.1136/ard.2008.101121
14. Genovese M. C., Becker J., Schiff M., Luggen M., Sherrer Y., Kremer J., Birbara C., Box J., Natarajan K., Nuamah I., Li T., Aranda R., Hagerty D. T., Dougados M., Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. New England Journal of Medicine 2005 353 11 1114 1123 2-s2.0-24944498854 10.1056/NEJMoa050524 (Pubitemid 41317434)
15. Kremer J. M., Genant H. K., Moreland L. W., Russell A. S., Emery P., Abud-Mendoza C., Szechinski J., Li T., Ge Z., Becker J., Westhovens R., Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Annals of Internal Medicine 2006 144 12 865 876 2-s2.0-33745291091 (Pubitemid 46768126)
16. Westhovens R., Kremer J. M., Moreland L. W., Emery P., Russell A. S., Li T., Aranda R., Becker J., Qi K., Dougados M., Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. Journal of Rheumatology 2009 36 4 736 742 2-s2.0-66149093043 10.3899/jrheum.080813
17. Lekpa F. K., Farrenq V., Canouï-Poitrine F., Paul M., Chevalier X., Bruckert R., Bastuji-Garin S., Claudepierre P., Lack of efficacy of abatacept in axial spondylarthropathies refractory to tumor-necrosis-factor inhibition. Joint Bone Spine 2012 79 1 47 50 2-s2.0-84855661105 10.1016/j.jbspin.2011.02.018
18. Song I. H., Heldmann F., Rudwaleit M., Haibel H., Weiß A., Braun J., Sieper J., Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Annals of the Rheumatic Diseases 2011 70 6 1108 1110 2-s2.0-79955868460 10.1136/ard.2010.145946
19. Merrill J. T., Burgos-Vargas R., Westhovens R., Chalmers A., D'Cruz D., Wallace D. J., Bae S. C., Sigal L., Becker J.-C., Kelly S., Raghupathi K., Li T., Peng Y., Kinaszczuk M., Nash P., The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism 2010 62 10 3077 3087 2-s2.0-77957682858 10.1002/art.27601
20. Singh J. A., Wells G. A., Christensen R., Tanjong Ghogomu E., Maxwell L., Macdonald J. K., Filippini G., Skoetz N., Francis D., Lopes L. C., Guyatt G. H., Schmitt J., La Mantia L., Weberschock T., Roos J. F., Siebert H., Hershan S., Lunn M. P., Tugwell P., Buchbinder R., Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database of Systematic Reviews 2011 2 CD008794 2-s2.0-79953018875
21. Delle Sedie A., Riente L., Scirè C. A., Iagnocco A., Filippucci E., Meenagh G., Possemato N., Grassi W., Valesini G., Montecucco C., Bombardieri S., Ultrasound imaging for the rheumatologist XXIV. Sonographic evaluation of wrist and hand joint and tendon involvement in systemic lupus erythematosus. Clinical and Experimental Rheumatology 2009 27 6 897 901 2-s2.0-76649093587
22. Tsokos G. C., Mechanisms of disease: systemic lupus erythematosus. New England Journal of Medicine 2011 365 22 2110 2121 2-s2.0-82555196095
23. Lee Y. H., Harley J. B., Nath S. K., CTLA-4 polymorphisms and systemic lupus erythematosus (SLE): a meta-analysis. Human Genetics 2005 116 5 361 367 2-s2.0-17144378972 10.1007/s00439-004-1244-1 (Pubitemid 40521112)
24. Takeuchi T., Suzuki K., Kondo T., Yoshimoto K., Tsuzaka K., CD3 zeta defects in systemic lupus erythematosus. Annals of the Rheumatic Diseases 2012 71 supplement 2 i78 i81 2-s2.0-84859506368 10.1136/annrheumdis-2011-200641
25. Dörner T., Giesecke C., Lipsky P. E., Mechanisms of B cell autoimmunity in SLE. Arthritis Research and Therapy 2011 13 5 243 2-s2.0-81255146464 10.1186/ar3433